Ankylosing Spondylitis Treatment Market Size, Share And Global Trend By Treatment(Drugs, Physical Therapy, Surgery), By End User(Hospitals, Clinics, Ambulatory Surgery Centers), And Regional Forecast, 2024-2032

Ankylosing spondylitis (AS) is a form of arthritis that primarily affects the spine causing long term inflammation of spine, shoulder, and hip joints. As spondylitis progress between the joints of ribs and spine, it eventually restricts the movement of the chest making it difficult to breathe properly. Ankylosing spondylitis in its advanced stage causes vertebrae fractures. Pain and swelling in a finger or toe, tenderness at the base of the pelvis, chest pain and tiredness are some of the symptoms associated with ankylosing spondylitis which generally appears in the age group 17 to 45 years or during late adolescence. Currently, there is no specific cure for ankylosing spondylitis, but some of the treatments and medications are available to reduce the symptoms and helps in the management of the pain.

Nonsteroidal anti-inflammatory drugs (NSAIDs), biologics including anti-TNF and anti-IL-17 drugs are some of the medications used to reduce the pain and swelling. Frequent back exercise and fitness activities can also aid in managing the symptoms associated with ankylosing spondylitis. Growing demand for effective therapies for the treatment of ankylosing spondylitis and emerging drugs under clinical trials are likely to boost the ankylosing spondylitis treatment market during the forecast period.

Increasing prevalence of ankylosing spondylitis, introduction of biologics in the market, rising awareness about new diagnostics methods, and emerging treatment options for ankylosing spondylitis are likely to drive the growth of ankylosing spondylitis treatment market during the forecast period. Additionally, growing initiatives by government in improving healthcare infrastructure and strong pipeline drugs are likely to fuel the growth of ankylosing spondylitis treatment market during the forecast period.

However, due to the lack of skilled surgeons in low-middle income countries, unavailability of effective drugs for the treatment, and high cost of the treatment are likely to hinder the ankylosing spondylitis treatment market during the forecast period.

Key Players Covered

Some of the major companies that are present in the global ankylosing spondylitis treatment market are AbbVie Inc., Janssen Pharmaceuticals Inc., Pfizer Inc., Sandoz International GmbH, Amgen Inc., Protalix BioTherapeutics, Inc., Reliance Life Sciences Pvt. Ltd., Momenta Pharmaceuticals Inc., Celgene Corporation, Regeneron Pharmaceuticals, Merck & Co. Inc., among others.

SEGMENTATION

Among treatment, immunotherapy drugs segment is anticipated to hold the largest market share during the forecast period as they are considered as more safe and effective than nonsteroidal anti-inflammatory drugs. For instance, in 2018, Eli Lilly and Company have announced positive results of Taltz (ixekizumab) which was in phase-3 for the treatment of ankylosing spondylitis (AS).

Key Insights

Overview of Pipeline Drugs

Advancements in Treatment of Ankylosing Spondylitis

Epidemiology Analysis of Ankylosing Spondylitis

The Regulatory Scenario of Key Countries/Regions

Recent Key Industry Developments – Mergers, Acquisitions, And Partnerships.

Regional Analysis

Geographically, the global ankylosing spondylitis treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America followed by Europe is anticipated to hold a considerable share of the global ankylosing spondylitis treatment market owing to growing investments in research and development activities, increasing adoption of ankylosing spondylitis treatment options, and increase in the prevalence of ankylosing spondylitis. In 2018, according to the state of musculoskeletal health reports, it was estimated that 200,000 people in the UK were affected by ankylosing spondylitis. Ankylosing spondylitis treatment market is likely to expand in Asia Pacific region at a significant rate owing to growing patient population, rise in the investments by government-funded organizations in improving the healthcare infrastructure in order to enhance the quality care of patients with ankylosing spondylitis.

Key Industry Developments     

• In February 2018, Eli Lilly and Company announced positive results of Taltz (ixekizumab) which was in phase-3 for the treatment of ankylosing spondylitis (AS).
• In October 2017, Janssen Global Services, LLC, received FDA approval to use SIMPONI ARIA the only fully-human anti-tumor necrosis factor (TNF)-alpha therapy used for the treatment of adults with active psoriatic arthritis (PsA) or active ankylosing spondylitis (AS).
• In January 2016, Novartis AG received FDA approval to use Cosentyx to treat patients suffering from ankylosing spondylitis and psoriatic arthritis.